372 related articles for article (PubMed ID: 15077220)
21. Prediction of reactivity to noninherited maternal antigen in MHC-mismatched, minor histocompatibility antigen-matched stem cell transplantation in a mouse model.
Araki M; Hirayama M; Azuma E; Kumamoto T; Iwamoto S; Toyoda H; Ito M; Amano K; Komada Y
J Immunol; 2010 Dec; 185(12):7739-45. PubMed ID: 21078914
[TBL] [Abstract][Full Text] [Related]
22. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
[TBL] [Abstract][Full Text] [Related]
23. Minor histocompatibility antigens: presentation principles, recognition logic and the potential for a healing hand.
Spencer CT; Gilchuk P; Dragovic SM; Joyce S
Curr Opin Organ Transplant; 2010 Aug; 15(4):512-25. PubMed ID: 20616723
[TBL] [Abstract][Full Text] [Related]
24. The relevance of minor histocompatibility antigens in solid organ transplantation.
Dierselhuis M; Goulmy E
Curr Opin Organ Transplant; 2009 Aug; 14(4):419-25. PubMed ID: 19444105
[TBL] [Abstract][Full Text] [Related]
25. Exploiting beneficial alloreactive T cells.
Barber LD; Madrigal JA
Vox Sang; 2006 Jul; 91(1):20-7. PubMed ID: 16756597
[TBL] [Abstract][Full Text] [Related]
26. Minor histocompatibility antigens: targets for tumour therapy and transplant tolerance.
Spierings E
Int J Immunogenet; 2008 Aug; 35(4-5):363-6. PubMed ID: 18976439
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of cancer through targeting of minor histocompatibility antigens.
Hambach L; Goulmy E
Curr Opin Immunol; 2005 Apr; 17(2):202-10. PubMed ID: 15766682
[TBL] [Abstract][Full Text] [Related]
28. T cell immunity and graft-versus-host disease (GVHD).
Ichiki Y; Bowlus CL; Shimoda S; Ishibashi H; Vierling JM; Gershwin ME
Autoimmun Rev; 2006 Jan; 5(1):1-9. PubMed ID: 16338205
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic hematopoietic stem-cell transplantation: the next generation of therapy for metastatic renal cell cancer.
Arya M; Chao D; Patel HR
Nat Clin Pract Oncol; 2004 Nov; 1(1):32-8. PubMed ID: 16264797
[TBL] [Abstract][Full Text] [Related]
30. Minor histocompatibility antigens: past, present, and future.
Spierings E
Tissue Antigens; 2014 Oct; 84(4):374-60. PubMed ID: 25262921
[TBL] [Abstract][Full Text] [Related]
31. Minor histocompatibility antigens as risk factor for poor prognosis in kidney transplantation.
Pabón MA; Navarro CE; Martin R; Rodríguez M; Martin I; Gaitán L; Gómez A; Lozano E
Transplant Proc; 2011 Nov; 43(9):3319-23. PubMed ID: 22099788
[TBL] [Abstract][Full Text] [Related]
32. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.
Griffioen M; Honders MW; van der Meijden ED; van Luxemburg-Heijs SA; Lurvink EG; Kester MG; van Bergen CA; Falkenburg JH
Haematologica; 2012 Aug; 97(8):1196-204. PubMed ID: 22419570
[TBL] [Abstract][Full Text] [Related]
33. Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia.
Falkenburg JH; Willemze R
Best Pract Res Clin Haematol; 2004 Sep; 17(3):415-25. PubMed ID: 15498713
[TBL] [Abstract][Full Text] [Related]
34. ABO glycosyltransferases as potential source of minor histocompatibility antigens in allogeneic peripheral blood progenitor cell transplantation.
Eiz-Vesper B; Seltsam A; Blasczyk R
Transfusion; 2005 Jun; 45(6):960-8. PubMed ID: 15934995
[TBL] [Abstract][Full Text] [Related]
35. Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens.
Fuchs KJ; Honders MW; van der Meijden ED; Adriaans AE; van der Lee DI; Pont MJ; Monajemi R; Kielbasa SM; 't Hoen PAC; van Bergen CAM; Falkenburg JHF; Griffioen M
Front Immunol; 2020; 11():659. PubMed ID: 32362897
[TBL] [Abstract][Full Text] [Related]
36. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers.
Schilbach K; Schick J; Wehrmann M; Wollny G; Simon P; Schlegel PG; Eyrich M
Transplantation; 2007 Jul; 84(2):214-22. PubMed ID: 17667813
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease.
Natzke AM; Shaw JL; McKeller MR; Emo KL; Mullen CA
Biol Blood Marrow Transplant; 2007 Jan; 13(1):34-45. PubMed ID: 17222751
[TBL] [Abstract][Full Text] [Related]
38. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
Zilberberg J; Feinman R; Korngold R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643
[TBL] [Abstract][Full Text] [Related]
39. A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution.
Holloway PA; Kaldenhoven N; Kok-Schoemaker HM; Dijk Mv; Otten HG; Tilanus M; Postma S; Mutis T; Lokhorst HM; Bloem AC
Br J Haematol; 2005 Jan; 128(1):73-81. PubMed ID: 15606552
[TBL] [Abstract][Full Text] [Related]
40. [Allogeneic hematopoietic stem cell transplantation for solid tumors].
Kanda Y
Rinsho Ketsueki; 2004 Mar; 45(3):189-94. PubMed ID: 15103931
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
